Evidence map›Paper›PMID 40796942›Full record

ArticleScientific reports2025

RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.

Kyle C Strickland, Zachary D Wallen, Heidi C Ko, Michelle F Green, Alicia Dillard, Sarabjot Pabla, Stephanie Hastings, Alison Roos, Taylor J Jensen, Marcia Eisenberg and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Kyle C StricklandLabcorp, 10 Moore Dr, Durham, NC, 27703, USA. kyle.strickland@labcorp.com.
Zachary D WallenLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Heidi C KoLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Michelle F GreenLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Alicia DillardLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Sarabjot PablaLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Stephanie HastingsLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Alison RoosThermo Fisher Scientific, Carlsbad, CA, 92008, USA.
Taylor J JensenLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Marcia EisenbergLabcorp, Burlington, NC, 27215, USA.
Brian J CaveneyLabcorp, Burlington, NC, 27215, USA.
Shakti RamkissoonLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Eric A SeversonLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.
Rebecca A PrevisLabcorp, 10 Moore Dr, Durham, NC, 27703, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) is a molecularly heterogeneous and lethal malignancy, with late-stage diagnosis contributing to high risk of recurrence and poor clinical outcomes. Although homologous recombination (HR) deficiency and retinoblastoma gene (RB1) expression have been implicated in prognosis, their combined role in shaping tumor biology and survival outcomes is not well defined. To investigate the relationship between HR status and RB1 expression and explore their potential as a combined prognostic marker, we analyzed data from two cohorts: (1) 272 HGSOC cases from The Cancer Genome Atlas (TCGA) with RB1 mRNA expression data and HR status previously annotated by Takaya et al. (HR-deficient, HRD; HR-proficient, HRP), and (2) 226 clinical HGSOC cases profiled by comprehensive genomic and immune profiling (CGIP) at OmniSeq, categorized as either HR-intact (HRi) or harboring BRCA1/2 alterations (BRCAa). Cases were additionally stratified according to RB1 mRNA expression level as RB1-high (> 25th percentile; RBH) or RB1-low (≤ 25th percentile; RBL). HRP-RBH tumors (n = 120, 44.1%) were associated with significantly worse overall survival (OS) and progression free survival (PFS) compared to all other subgroups. Survival metrics were evaluated from the TCGA cohort and demonstrated that median OS for HRP-RBH was 35.9 mo, shorter than HRP-RBL (52.0 mo), HRD-RBL (57.1 mo), and HRD-RBH subgroups (53.3 mo; all p < 0.0001). PFS demonstrated a similar trend (15.1 mo vs. 20.6, 20.2 and 20.4 mo, respectively, p = 0.0021). HRP-RBH tumors also showed higher aneuploidy scores (median 18 vs. ≤ 10.5 in other subgroups, all p < 0.01). From the OmniSeq cohort, HRi-RBH tumors exhibited a distinct immune gene signature, including elevated mRNA expression of 213 differentially expressed genes and enrichment of pathways such as EMT, PI3K/AKT signaling, and interleukin signaling. Overall, this study suggests that molecular subtyping of HGSOC based on HR status and RB1 expression may provide valuable prognostic insight. HRP tumors with high RB1 expression represent a high-risk subgroup with a distinct molecular profile and poor clinical outcomes, underscoring the need for novel therapeutic strategies targeting this aggressive subset. These findings provide a foundation for future studies aimed at developing biomarkers and treatments tailored to this challenging subset of HGSOC patients.

Indexed as

Cystadenocarcinoma, SerousHomologous RecombinationOvarian NeoplasmsRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesGynecologic oncologyHigh grade serous ovarian carcinomaHomologous recombination deficiencyOvarian cancerPapillary serous adenocarcinomaRB1

Identifiers

PMID40796942
PMCPMC12343831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.